ClearID tracks changes in The Testing ... - Sterling Path

1 ClearID tracks changes in the body at a cellular level The Challenge Knowing how your body is responding to therapy in real-time is critical when you are targeting disease. Having timely information on biological changes in your body is key to your vigilant efforts to defend your health. In certain cases, today s standard methods for assessing tumors including imaging and tissue biopsy may not provide all of the information needed to accurately guide a treatment path . This can be due to the lack of access to tumor tissue samples, or the inability of current technologies to identify very small changes that may be happening in the body. More Information = Better Outcomes The success of the cancer treatments of today and tomorrow hinge on the ability to track changes in an individual s body at a cellular level using safe and easily-repeatable Testing methods.

2 Due to significant advances in DNA sequencing technology, a simple blood draw can now be used to monitor a patient through the entire treatment cycle, helping to determine the most effective targeted treatments, while tracking the individual s response to that treatment. With the ability to find and analyze specific biomarkers in the blood that are associated with cancer, doctors are better equipped to make quicker, more informed medical decisions leading to better patient outcomes. The Testing Process A test kit and requisition form is ordered by your doctor at or by calling Sterling Pathology. Two tubes of blood are drawn and sent along with a requisition form to the CLIA lab processing.* The blood sample is analyzed using next-generation sequencing for cancer-associated mutations.

3 A comprehensive and actionable test report is securely sent to your doctor within 8 days. *Fasting is not required prior to a ClearID test. Order Inquiries Contact Sterling Pathology Monday to Friday 6am 7pm (Pacific). Call: (800) 899-8480 Visit: Test Processing Tests are processed in Cynvenio Biosystems CLIA lab located in Westlake Village, CA. For more information about Cynvenio, visit highly sensitive genomic blood test to identify, track and target cancer in Information 2015 Cynvenio Biosystems, Inc. All rights reserved. 1234 Not your average blood test: The ClearID solution ClearID is a genomic blood test that offers a Testing solution where traditional tissue biopsies may fall short. By targeting and analyzing the genes that are known to be associated with cancer, ClearID can aid doctors in treatment decisions or match patients with clinical trials that fit their specific genetic profile.

4 Metastatic Patients For a metastatic patient, for whom biopsy of a secondary tumor site may be difficult and painful, ClearID is a valuable tool that can identify and target cancer-associated mutations that may be the roots of metastasis. Lack of Tissue In those cases in which there is a lack of tissue to biopsy, ClearID can provide critical information via a standard blood draw. Regular Testing & Monitoring During a course of treatment, ClearID can be used as a minimally invasive method of regular Testing to monitor response to therapy without the need for additional is ClearID different than other tests? ClearID is different than other molecular tests because its analysis is performed on circulating cells taken from blood without the need for a biopsy procedure.

5 The test looks beyond the traditional tumor biomarkers at a comprehensive panel of genes associated with tumor progression. Because ClearID is a low-risk, low-pain blood test, information can be gathered more frequently than tissue biopsy, providing a real-time molecular snapshot molecular profile of each patient s tumor. How often should ClearID be performed? The frequency of ClearID Testing is determined by your doctor. It is advisable for high risk patients to be tested every 6 months in accordance with the NCCN guidelines. Which cancer types can ClearID can detect? ClearID provides reliable access to a variety of rare populations of cancer cells in whole blood. The test is best suited to patients diagnosed with breast cancer. Other cancer tests are in development.

6 Are there any complications from taking the ClearID test? The ClearID test is performed on blood obtained from a standard, minimally invasive blood draw. Therefore, the risk is minimal. How are ClearID results reported? ClearID results are summarized in a clear and concise, action-oriented genomic report that is tailored to each patient's unique molecular profile. This report includes clinically relevant and up-to-date information about existing therapies, new drugs in development, and active clinical trials - all curated by leading independent clinical practitioners. Each patient test report is securely emailed to the ordering physician within 8 days of the receipt of the patient s blood genetic Testing producing results in cancer care? Genetic Testing is helping to guide cancer treatment.

7 Numerous studies have shown that patients whose tumors were genotyped have experienced better overall survival odds than those who were not. Choosing the right therapy can significantly raise response rates in patients and may improve overall survival. Will genetic Testing improve my chances of beating cancer? In the past, doctors had few tools available for predicting which drugs would work for which patients. Instead, they had to start by using treatments that are accepted as working for most patients, and then move to more specialized treatments only if the patient failed to respond to the first line therapy. While there are no guarantees that a course of therapy will be effective, very good results have been achieved with targeted therapy, such as with Trastuzumab (Herceptin) for breast cancer.

8 Your oncologist can give you specific guidance on whether the ClearID test will be helpful in selecting targeted therapies that match genetic alterations identified with the test. I have not been diagnosed with cancer, but can I use results of ClearID to determine my risk? ClearID is not designed to assess an individual s risk of cancer. It is designed for evaluating a patient s circulating tumor cells once cancer has been Reporting Providing a path to ActionAnswers to your questions about ClearID Summary of cancer-associated mutations Recommended targeted therapies Active clinical trials Continuously updated informatio